NK cell-derived IL-10 enhances Plasmodium-specific CD4+ Tfh differentiation and IL-27 production in mice

Abstract Malaria, which results from infection with Plasmodium parasites, remains a major public health problem with over 200 million cases and nearly 500,000 deaths annually. Although long-lived, sterilizing immunity does not develop in humans following repeated exposure to Plasmodium parasites, protection against symptomatic disease correlates with the acquisition of humoral immunity. Despite the established role antibodies play in protection to malaria disease, excessive inflammation is thought to contribute to the ineffective immune response to Plasmodium infection. Plasmodium berghei ANKA (PbA) infection results in a fatal severe malaria disease in mice. We previously showed that treatment of mice with IL-15 complex (IL-15C; IL-15 bound to an IL-15Rα-Fc fusion protein) induces IL-10 expression in NK cells, which protects mice from PbA-induced death by dampening the fatal inflammatory response. Interestingly, IL-15C treatment promotes Tfh differentiation at 7 days post-PbA infection (dpi), and genetic deletion of NK cell-derived IL-10 or antibody blockade of IL-10R prevents IL-15C-induced Tfh differentiation. Additionally, IL-15C treatment enhances CD4 T cell-derived IL-27p28 production at 7 dpi and results in increased anti-PbA IgG antibody levels at 42 dpi. These data suggest that IL-15C treatment, via its induction of IL-10 from NK cells, modulates the inflammatory milieu to promote Tfh differentiation, IL-27 production, and PbA-specific antibody generation. These findings will facilitate improved control of malaria infection and protection from disease by informing therapeutic strategies and vaccine design. Supported by grants from NIH (K22 AI143969-01A1, K08 AI141761-01)